The U.S. Food and Drug Administration (FDA) announced on Wednesday, Mar. 4, the approval of Opdivo (nivolumab) as treatment for patients suffering from metastatic squamous non-small cell lung cancer (NSCLC) that has progressed after or while on platinum-based chemotherapy. The cancer drug marketed by Bristol-Myers Squibb was reviewed as NSCLC treatment under the priority review program of the FDA,